Today's Pre-Open Stock Movers:

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) 40.7% LOWER; announced topline results from its 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF). The study enrolled patients in the U.S., Canada and Europe at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF.

Oragenics, Inc. (NYSE: OGEN) 30% HIGHER; announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (FDA) that it is in broad agreement with the Companys planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a result, the Company believes its timelines for both filing an Investigational New Drug (IND) application and the commencement of the Phase 1 study will proceed on schedule. Oragenics expects to file the IND by the end of the first quarter of 2021 and commence patient enrollment in the Phase 1 clinical study early in the second quarter of 2021.

Alteryx, Inc. (NYSE: AYX) 22.9% HIGHER; announced that Mark Anderson, a current member of Alteryx's Board of Directors, has been appointed to succeed Dean Stoecker, Alteryx's Co-founder, Chairman and current Chief Executive Officer, as Alteryx's Chief Executive Officer, effective today. Q3 revenue guidance beats.

Jaguar Health, Inc. (NASDAQ: JAGX) 12.9% HIGHER; met the financial condition for the initial $5 million tranche of the previously announced non-dilutive royalty financing transaction - which has the potential to total $16 million - involving the sale of royalty rights related to the future revenue stream for the company's FDA-approved drug product, Mytesi (crofelemer).

Vir Biotechnology, Inc. (Nasdaq: VIR) 10.7% HIGHER; Vir and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). Following a positive assessment of unblinded safety data from the lead-in portion of the trial by an Independent Data Monitoring Committee on September 30, 2020, the COMET-ICE registrational study will now expand globally to additional sites in North America, South America and Europe.

BioNTech SE (Nasdaq: BNTX) 8% HIGHER; Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies vaccine development program against COVID-19. The EMAs decision to start a rolling review follows the encouraging preliminary results from pre-clinical and early clinical studies in adults, which suggest that BNT162b2 triggers the production of neutralizing antibodies and TH-1 dominant CD4+ and CD8+ T cells that target SARS-CoV-2. A combination of an antibody and T cell response is believed to be important in eliciting protection against viral infection and disease. BioNTech and Pfizer plan to work with the EMAs Committee for Medicinal Products for Human Use (CHMP) to complete the rolling review process to facilitate the final Marketing Authorization Application (MAA).

Logitech (NASDAQ: LOGI) 6.2% LOWER; Apple removed competing speakers and headsets from its online stores.

Sonos (NASDAQ: SONO) 5.7% LOWER; Apple removed competing speakers and headsets from its online stores.

Advance Auto Parts (NYSE: AAP) 2.7% HIGHER; JPMorgan upgraded from Neutral to Overweight with a price target of $190.00.

NVIDIA (NASDAQ: NVDA) 1.6% HIGHER; Oppenheimer raised the price target on to $600.00 (from $550.00).